Total Payments
$31,906
2024 Payments
$206.52
Companies
22
Transactions
80
Medicare Patients
5,287
Medicare Billing
$440,399
Payment Breakdown by Category
Research$13,394 (42.0%)
Consulting$9,513 (29.8%)
Other$4,960 (15.5%)
Travel$2,818 (8.8%)
Food & Beverage$1,205 (3.8%)
Education$15.33 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,394 | 7 | 42.0% |
| Consulting Fee | $9,513 | 2 | 29.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,960 | 9 | 15.5% |
| Travel and Lodging | $2,818 | 5 | 8.8% |
| Food and Beverage | $1,205 | 54 | 3.8% |
| Education | $15.33 | 3 | 0.0% |
Payments by Type
General
$18,512
73 transactions
Research
$13,394
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $13,371 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $6,675 | 8 | $0 (2024) |
| Eli Lilly and Company | $4,323 | 5 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,841 | 13 | $0 (2018) |
| Boehringer Ingelheim International GmbH | $1,731 | 5 | $0 (2023) |
| PFIZER INC. | $1,500 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $1,144 | 2 | $0 (2020) |
| Incyte Corporation | $585.00 | 1 | $0 (2018) |
| GlaxoSmithKline, LLC. | $197.03 | 2 | $0 (2018) |
| Tempus AI, Inc | $119.15 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $206.52 | 7 | Tempus AI, Inc ($119.15) |
| 2023 | $844.37 | 7 | Boehringer Ingelheim International GmbH ($695.91) |
| 2022 | $1,106 | 7 | Boehringer Ingelheim International GmbH ($1,035) |
| 2020 | $7,707 | 4 | Merck Sharp & Dohme Corporation ($6,538) |
| 2019 | $3,031 | 12 | Celgene Corporation ($2,883) |
| 2018 | $7,125 | 11 | Celgene Corporation ($6,310) |
| 2017 | $11,886 | 32 | Eli Lilly and Company ($4,323) |
All Payment Transactions
80 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $14.71 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $18.06 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $28.96 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $20.39 | General |
| 06/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.47 | General |
| Category: Hematology | ||||||
| 06/01/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $84.05 | General |
| 04/27/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Oncology | ||||||
| 11/16/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $30.67 | General |
| Category: Hematology | ||||||
| 11/16/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $29.19 | General |
| Category: Hematology | ||||||
| 06/07/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $35.50 | General |
| Category: Hematology | ||||||
| 05/03/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $33.47 | General |
| 04/13/2023 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $505.55 | General |
| 02/08/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Oncology | ||||||
| 01/12/2023 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $190.36 | General |
| 10/28/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $403.94 | General |
| 10/28/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $190.36 | General |
| 08/24/2022 | Genentech USA, Inc. | GAZYVA (Biological), VENCLEXTA | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: BioOncology | ||||||
| 08/16/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $10.85 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA, WELIREG | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $440.66 | General |
| 03/02/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2020 | Merck Sharp & Dohme Corporation | MK-5618 (Drug) | Consulting Fee | Cash or cash equivalent | $6,537.66 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2020 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $605.91 | General |
| 07/04/2020 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $538.58 | General |
| 02/20/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AZA-ST-001 - A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors | Celgene Corporation | $3,444 | 1 |
| CC-122-ST-001 - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Celgene Corporation | $2,866 | 1 |
| Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (CC-122-ST-001) | Celgene Corporation | $2,866 | 1 |
| AZA-ST-001 | Celgene Corporation | $2,533 | 1 |
| CC-122-ST-001 CC-122-DLBCL-001 | Celgene Corporation | $1,488 | 1 |
| A PHASE II, OPEN LABEL, RANDOMIZED, TWO-ARM STUDY TO INVESTIGATE THE E | GlaxoSmithKline, LLC. | $122.23 | 1 |
| A PHASE I, OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY | GlaxoSmithKline, LLC. | $74.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 663 | 3,351 | $315,390 | $79,443 |
| 2022 | 40 | 1,443 | 5,351 | $386,215 | $101,936 |
| 2021 | 35 | 1,387 | 6,441 | $435,225 | $120,010 |
| 2020 | 45 | 1,794 | 6,910 | $498,521 | $139,009 |
Total Patients
5,287
Total Services
22,053
Medicare Billing
$440,399
Procedure Codes
142
All Medicare Procedures & Services
142 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 112 | 496 | $130,640 | $34,280 | 26.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 55 | 241 | $90,827 | $23,531 | 25.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 20 | 84 | $17,252 | $4,173 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 41 | $15,287 | $4,091 | 26.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 28 | 138 | $11,859 | $3,048 | 25.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 74 | 218 | $6,906 | $2,256 | 32.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 69 | 206 | $4,802 | $1,568 | 32.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 32 | $5,904 | $1,553 | 26.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 25 | 92 | $5,336 | $1,092 | 20.5% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 19 | 31 | $4,061 | $893.11 | 22.0% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 21 | 26 | $3,562 | $655.98 | 18.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 54 | $2,538 | $595.08 | 23.4% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 20 | 48 | $2,016 | $474.58 | 23.5% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 470 | $11,030 | $416.94 | 3.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 11 | 18 | $1,074 | $271.04 | 25.2% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 15 | 19 | $368.79 | $120.46 | 32.7% |
| 85730 | Coagulation assessment blood test, plasma or whole blood | Office | 2023 | 16 | 16 | $288.48 | $94.24 | 32.7% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 24 | 109 | $356.97 | $91.09 | 25.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 18 | 950 | $359.20 | $90.11 | 25.1% |
| 85610 | Blood test, clotting time | Office | 2023 | 17 | 17 | $218.79 | $71.40 | 32.6% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 20 | 31 | $574.25 | $62.77 | 10.9% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 11 | 14 | $129.40 | $14.37 | 11.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 118 | 486 | $129,047 | $34,296 | 26.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 69 | 293 | $116,940 | $30,539 | 26.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 30 | 157 | $32,245 | $8,136 | 25.2% |
About Dr. Drew Rasco, MD
Dr. Drew Rasco, MD is a Internal Medicine healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558311225.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Drew Rasco, MD has received a total of $31,906 in payments from pharmaceutical and medical device companies, with $206.52 received in 2024. These payments were reported across 80 transactions from 22 companies. The most common payment nature is "" ($13,394).
As a Medicare-enrolled provider, Rasco has provided services to 5,287 Medicare beneficiaries, totaling 22,053 services with total Medicare billing of $440,399. Data is available for 4 years (2020–2023), covering 142 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location San Antonio, TX
- Active Since 05/11/2006
- Last Updated 07/11/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1558311225
Products in Payments
- CC-122 (Drug) $7,237
- MK-5618 (Drug) $6,538
- CC-486 (Drug) $5,995
- KEYTRUDA (Biological) $104.33
- Pomalyst (Drug) $95.36
- CYRAMZA (Drug) $63.89
- Stivarga (Drug) $58.33
- GILOTRIF (Drug) $44.63
- ALIMTA (Drug) $38.72
- OPDIVO (Biological) $35.61
- REBLOZYL (Biological) $24.47
- Enhertu (Drug) $24.36
- GAZYVA (Biological) $21.85
- PROMACTA (Drug) $19.63
- RYDAPT (Drug) $18.95
- Kyprolis (Biological) $18.65
- Herceptin (Biological) $18.22
- OPDUALAG (Drug) $18.06
- Bavencio (Biological) $16.63
- Xospata (Drug) $15.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Antonio
Hemal Nayak, Md, MD
Internal Medicine — Payments: $642,605
Internal Medicine $642,605
Dr. Allen Anderson, Md, MD
Internal Medicine — Payments: $444,990
Internal Medicine $444,990
Montaser Shaheen, M.d, M.D
Internal Medicine — Payments: $300,958
Internal Medicine $300,958
Shahid Aziz, M.d, M.D
Internal Medicine — Payments: $281,598
Internal Medicine $281,598
Dr. Ali Abedi, M.d, M.D
Internal Medicine — Payments: $257,382
Internal Medicine $257,382
Dr. Manuel Rodriguez, M.d, M.D
Internal Medicine — Payments: $187,632
Internal Medicine $187,632